Amicus Therapeutics is one of the finest new biomed companies in the world, and they are focused on researching and releasing drugs that make a difference in the world. They have built a business based purely on the strength of their research, and they are hoping to release drugs to the public that will cure many diseases. This article explains how the company has invested in helping those who need it most.
#1: What Is The Purpose Of Biomed?
The biomed industry works with pharmaceuticals that will help cure illnesses from the cellular level. These companies are working on research that will help them create drugs that may be used in trials, and they hope that these drugs will go quite a long way to ensuring that the doctors and patients will see results(https://seekingalpha.com/article/4073303-amicus-therapeutics-small-biotech-seems-big-mo). They have many trusted partners, and they are looking into drugs that will cure a number of ailments.
#2: Trial Doctors Trust Amicus
Amicus Therapeutics has a number of trial doctors on their rolls that trust them with their patients. These doctors are given every opportunity to make a difference in the lives of patients, and they are reporting on drug trials that may change lives. They will participate in every new trial that Amicus has to offer, and they are giving the company a chance to bring the drug to a larger market.
#3: Growing Every Year
Amicus Therapeutics is growing every year in sales and trials(Yahoo Finance) . They want to have doctors working with them who are familiar with their work, and they want to help teach new doctors about the drugs they are building. This collaborative process works in favor of all patients, and patients who are lucky enough to be in their trials often see amazing results beyond anything they could have imagined.
Amicus Therapeutics has created a drug trial system that will grow their business and patient health. Their trial doctors help them release new drugs every year, and they are growing enough to release even more drugs to those who need them. Their commitment to biopharmaceuticals is unmatched across the industry.
More here: Twitter | Facebook
Foresite Capital recently announced that it was bringing on board Dr. Molly He to the company as a venture partner. This appointment is a big move for the company which has been diversifying its investments into other fields of healthcare and also venturing into new markets across the globe. Dr. He brings to the table more than 15 years of experience and is expected to be an invaluable asset to the company as a whole especially when it comes to the evaluation of new investment prospects within the healthcare industry.
Speaking during the announcement which was made at the company’s headquarters in San Francisco, Dr. Jim Tananbaum described her as one of the leading and most respected research scientists in the world when it comes to matters dealing with next generation sequencing. Jim Tananbaum is the founder and current CEO of Foresite Capital, an equity firm that supports investment in healthcare companies working both within the private sector and in the public sector. Before coming to Foresite Capital, Dr. He worked at Illumina where she held the position of senior director. Most of her labor and research involved genomic and pharmaceutical research and development, a field that Foresite Capital is keen on pursuing and making an investment.
Jim Tananbaum is a trained and certified medical practitioner although most people know him more for his work as a venture capitalist than as a physician. His academic qualifications are not to be questioned as he is a holder of a BSEE and a BS from Yale University as well as an MS from MIT an MD from Harvard Medical School and finally an MBA earned from the Harvard Business School.
As a venture capitalist, Jim Tananbaum has been the man behind the funding for many healthcare investments in the US and some of his most notable investments include Amerigroup, Jazz Pharmaceuticals, Healtheon and Amira Pharmaceuticals. He currently serves as Foresite Capital’s Chef Executive Officer, a position that he had held since 2010 when he founded the company. So far he has more than 25 years of experience in both the medical and financial world, and it is these qualities that have propelled the company to where it is today. More details can be found on Bloomberg.